The heparin market is projected to grow at a CAGR of 7.02% during 2027–2032. Asia-Pacific leads the market, while growing interest in biosynthetic alternatives and diversified raw material sources is reshaping the industry.

Hyderabad, India, Oct. 26, 2026 (GLOBE NEWSWIRE) -- According to the latest report by Mordor Intelligence, the heparin market size is projected to grow from USD 10.73 billion in 2026 to USD 11.51 billion in 2027, reaching USD 16.16 billion by 2032, at a CAGR of 7.02% during the 2027–2032 forecast period. Market growth is supported by increasing demand for anticoagulant therapies in surgical procedures, cardiovascular care, dialysis, and the management of thromboembolic disorders. Expanding healthcare requirements and ongoing efforts to strengthen pharmaceutical supply chains are further shaping the market. 

The heparin market continues to play an important role in modern healthcare because of the drug's established use in preventing and treating blood clot formation. Hospitals rely on heparin for anticoagulation during cardiovascular and orthopedic surgeries, while dialysis centers use it to help prevent clotting during treatment. Increasing healthcare utilization, a growing burden of cardiovascular conditions, and rising demand for renal replacement therapies are supporting consumption across clinical settings. Low-molecular-weight heparin is also widely used because of its predictable anticoagulant effects and suitability for several treatment and prevention protocols. 

 Heparin Market Share by Region 

Asia-Pacific accounted for 32.10% of the global heparin market in 2025, supported by established pharmaceutical ingredient manufacturing, rising healthcare expenditure, and increasing demand for anticoagulation therapies. China remains an important manufacturing center for heparin-related raw materials and active pharmaceutical ingredients, while India and other regional markets are investing in pharmaceutical production capabilities. Growing surgical volumes, expanding dialysis services, and improving access to hospital-based treatment are expected to support further regional growth. 

North America represents a significant market for heparin, supported by advanced healthcare infrastructure, substantial surgical volumes, and established treatment pathways for cardiovascular conditions and thromboembolic disorders. Demand from hospitals, dialysis centers, and specialized treatment facilities contributes to market consumption. Efforts to diversify raw material sources and strengthen domestic pharmaceutical supply chains are also influencing procurement strategies and investment priorities. 

Europe maintains an important position in the heparin market, driven by established healthcare systems, an aging population, and continued demand for anticoagulation in surgical and cardiovascular care. The region's emphasis on pharmaceutical quality, product safety, and regulatory compliance shapes supplier selection and manufacturing practices. Demand for low-molecular-weight heparin and ongoing research into alternative production methods are also influencing the regional competitive landscape. 

“Demand for heparin continues to be supported by its essential role in anticoagulation, surgical procedures, and dialysis care. Ongoing efforts to diversify raw material sources and develop biosynthetic alternatives are creating opportunities for manufacturers to strengthen supply reliability and address evolving healthcare requirements,” says Soumya Goud, Senior Research Manager, Mordor Intelligence. 

Heparin Market Trends & Forecast 

Rising Demand for Anticoagulation in Surgical Procedures and Dialysis 

Increasing surgical volumes and the expansion of dialysis services are supporting demand for heparin across healthcare settings. The drug is used in clinical protocols that require anticoagulation, including selected cardiovascular procedures and extracorporeal treatments. The rising prevalence of kidney disease and thromboembolic conditions is contributing to sustained demand from hospitals and specialized treatment centers. Hemodialysis is projected to be the fastest-growing application segment, registering a CAGR of 7.80% through 2031, reflecting the increasing importance of anticoagulation in renal care. 

Growing Adoption of Low-Molecular-Weight Heparin 

Low-molecular-weight heparin held 63.10% of the heparin market by product type in 2025, supported by its established role in the prevention and treatment of thromboembolic disorders. Its predictable pharmacological profile and suitability for subcutaneous administration make it an important option in hospital and selected outpatient care settings. Continued use in thrombosis prevention, surgical care, and other clinical applications is expected to support demand throughout the forecast period. At the same time, synthetic and biosynthetic heparin products are attracting interest as manufacturers seek alternative production approaches. 

Supply Diversification and Development of Biosynthetic Heparin 

Dependence on animal-derived raw materials remains an important consideration for heparin manufacturers. Supply disruptions and concerns about sourcing concentration have encouraged greater attention to alternative production methods and raw material diversification. Recombinant microbial sources are emerging as a potential avenue for improving supply resilience, while bovine-derived ingredients are receiving renewed attention as another sourcing option. Recombinant microbial heparin is projected to grow at a CAGR of 9.10% through 2031, reflecting increasing interest in alternatives to conventional animal-derived supply. 

Expansion of Pre-Filled Delivery Systems and Home-Based Care 

Pre-filled syringes and other convenient delivery formats are gaining relevance as healthcare providers seek to simplify administration and support treatment outside traditional hospital settings. Home-care settings are projected to be the fastest-growing end-user segment by 2031. This development creates opportunities for manufacturers to improve delivery convenience while maintaining product quality and appropriate safety standards. Hospitals are expected to remain the principal end-user segment, supported by their role in surgical procedures and acute care. 

Heparin Market Segmentation Overview 

The heparin market is segmented by product, source, dosage form, route of administration, application, end user, and geography. 

By Product 

  • Unfractionated Heparin 
  • Low-Molecular-Weight Heparin (LMWH) 
  • Ultra-Low-Molecular-Weight Heparin (ULMWH) 
  • Synthetic and Biosynthetic Heparin 

By Source 

  • Porcine 
  • Bovine 
  • Recombinant Microbial 

By Dosage Form 

  • Injectable Solution 
  • Pre-Filled Syringe 
  • Other Dosage Forms 

By Route of Administration 

  • Intravenous 
  • Subcutaneous 

By Application 

  • Deep Vein Thrombosis (DVT) 
  • Atrial Fibrillation and Heart Attack 
  • Coronary Artery Disease 
  • Hemodialysis 
  • Other Applications 

By End User 

  • Hospitals 
  • Ambulatory Surgical Centers 
  • Specialty Clinics 
  • Home-Care Settings 

By Geography 

  • North America 
  • United States 
  • Canada 
  • Mexico 
  • Europe 
  • Germany 
  • United Kingdom 
  • France 
  • Italy 
  • Spain 
  • Rest of Europe 
  • Asia-Pacific 
  • China 
  • Japan 
  • India 
  • South Korea 
  • Australia 
  • Rest of Asia-Pacific 
  • Middle East and Africa 
  • GCC 
  • South Africa 
  • Rest of Middle East and Africa 
  • South America 
  • Brazil 
  • Argentina 
  • Rest of South America 

The market's segmentation reflects the importance of established anticoagulation therapies alongside emerging production technologies and evolving care settings. Low-molecular-weight heparin accounted for the largest product share in 2025, while synthetic and biosynthetic heparin is expected to expand as manufacturers explore alternative supply sources. Porcine-derived material continues to dominate the source segment, although recombinant microbial production is gaining attention. By application, deep vein thrombosis accounted for the largest share, while hemodialysis is expected to grow more rapidly. Hospitals remain the leading end-user segment, with home-care settings emerging as an important growth opportunity. 

For a full breakdown of market dynamics, segmentation insights, regional analysis, and competitive landscape, access the details of the Mordor Intelligence report: 

https://www.mordorintelligence.com/industry-reports/heparin-market?utm_source=globenewswire 

Heparin Market Competitive Outlook 

The heparin market includes established pharmaceutical companies and specialized manufacturers of anticoagulant products and active pharmaceutical ingredients. Competition is shaped by product quality, manufacturing capacity, regulatory compliance, raw material availability, and the ability to maintain a reliable supply to healthcare providers. Established pharmaceutical companies continue to serve hospitals and other healthcare facilities, while specialized Asian manufacturers play an important role in ingredient production and global supply. 

Supply-chain diversification is becoming a strategic priority as companies seek to reduce exposure to disruptions affecting animal-derived raw materials. Manufacturers are assessing alternative sourcing arrangements, expanding production capabilities, and exploring biosynthetic technologies to improve supply reliability. Product development in low-molecular-weight heparin and convenient delivery systems is also influencing competition. Companies that can combine consistent quality, regulatory compliance, and dependable supply are positioned to respond to evolving healthcare requirements. 

Heparin Industry Leaders 

  • Pfizer Inc. 
  • Baxter International Inc. 
  • Sanofi 
  • Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. 

Check Out Related Reports Published by Mordor Intelligence 

Anti-Aging Market 

The Anti-Aging Market is expected to grow from USD 97.46 billion in 2027 to USD 135 billion by 2032, registering a CAGR of 6.74%, supported by rising consumer interest in healthy aging, increasing demand for skincare and aesthetic treatments, and growing adoption of non-invasive anti-aging procedures.  

Paracetamol Market 

The Paracetamol Market is projected to expand from USD 12.58 billion in 2027 to USD 15.39 billion by 2032, at a CAGR of 4.12%, driven by continued demand for pain and fever relief, widespread use of over-the-counter medications, and the availability of paracetamol in multiple formulations.  

Penicillin Drug Market  

The Penicillin Drug Market is expected to grow from USD 10.72 billion in 2026 to USD 12.68 billion by 2031, registering a CAGR of 3.41%, supported by ongoing demand for antibiotic treatments, the continued use of penicillin-based drugs for susceptible bacterial infections, and the need to manage common infectious diseases. 

About Mordor Intelligence 

Mordor Intelligence is a global market intelligence firm, founded in 2014, helping businesses make informed decisions through data-driven insights, industry expertise, and advanced analytics. With 550+ domain experts and on-ground specialists across 150+ countries, the company delivers comprehensive intelligence across aerospace & defense, agriculture, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, and logistics. 

Its offerings include syndicated industry reports, custom research and advisory, and subscription platforms such as Synapse, Data Center Intelligence, and Robotics Intelligence. Mordor Intelligence is ISO 9001:2015 and ISO/IEC 27001:2022 certified, a member of ESOMAR and the Market Research Society of India, and a four-time Great Place to Work® honoree. Learn more at mordorintelligence.com. 



CONTACT: For any inquiries or to access the full report, please contact:  

media@mordorintelligence.com  

https://www.mordorintelligence.com